These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Reversible cognitive and neurological symptoms during valproic acid therapy. Hommet C; Mondon K; de Toffol B; Constans T J Am Geriatr Soc; 2007 Apr; 55(4):628. PubMed ID: 17397449 [No Abstract] [Full Text] [Related]
5. Pseudoatrophy of the brain with valproic acid monotherapy. McLachlan RS Can J Neurol Sci; 1987 Aug; 14(3):294-6. PubMed ID: 3117347 [TBL] [Abstract][Full Text] [Related]
6. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Guerrini R; Belmonte A; Canapicchi R; Casalini C; Perucca E Epilepsia; 1998 Jan; 39(1):27-32. PubMed ID: 9578009 [TBL] [Abstract][Full Text] [Related]
7. Epilepsy: Should valproate be avoided during childbearing years? Maccotta L; Sullivan JE Nat Rev Neurol; 2009 Aug; 5(8):414-5. PubMed ID: 19657344 [No Abstract] [Full Text] [Related]
8. Valproate-induced hyperammonemia as a cause of altered mental status. Feil D; Chuang K; Sultzer DL Am J Geriatr Psychiatry; 2002; 10(4):476-8. PubMed ID: 12095907 [TBL] [Abstract][Full Text] [Related]
9. Reversible dementia and gait disturbance after prolonged use of valproic acid. Evans MD; Shinar R; Yaari R Seizure; 2011 Jul; 20(6):509-11. PubMed ID: 21435910 [TBL] [Abstract][Full Text] [Related]
10. Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient. Abreu LN; Issler C; Lafer B Aust N Z J Psychiatry; 2009 May; 43(5):484-5. PubMed ID: 19382315 [No Abstract] [Full Text] [Related]
11. [Reversible Parkinsonism and cognitive impairment following treatment with valproate]. Toribio-Díaz ME; Morera-Guitart J; Palao-Duarte S Rev Neurol; 2008 Oct 1-15; 47(7):390-1. PubMed ID: 18841554 [No Abstract] [Full Text] [Related]